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Objectives: To compare two minimally invasive enilconazole infusion protocols for the treatment of 
canine sinonasal aspergillosis and evaluate the importance of complete endoscopic debridement in 
determining first treatment success rate.
Materials and MethOds: Data for 48 dogs with confirmed sinonasal aspergillosis treated with endoscopic 
debridement followed by per-endoscopic enilconazole infusion were collected. Twenty-four dogs were 
treated according to the previously published 1-hour infusion protocol and 24 dogs underwent a simpli-
fied 15-minute infusion protocol. Completeness of debridement, evaluated as partial or complete at 
the end of the procedure and outcome after one or several treatments were assessed in all dogs. 
Multi-variable analysis was performed to derive odds ratios and 95% confidence intervals.
results: The median duration of the simplified protocol – 92∙3 minutes (range 40 to 140) – was sub-
stantially shorter than the duration of the previous protocol – 201∙3 minutes (range 120 to 265). First 
treatment success rates were 58 and 62∙5% for the previous and simplified protocol, respectively. 
Overall treatment success rate was similar in both groups (96%). Complete debridement was associ-
ated with an improved first treatment success rate compared to partial debridement.
clinical significance: The simplified protocol is a valid alternative approach to the treatment of sinonasal 
aspergillosis. Completeness of endoscopic debridement before infusion is an important step for the 
success of treatment in canine sinonasal aspergillosis.
M. Girod’s current address is Internal Medicine Department, Centre Hospitalier Vétérinaire 
Frégis, Arcueil, France
Paper presented as an oral abstract at the 25th ECVIM congress in Lisbon.
INTRODUCTION
In dogs, mycotic rhinosinusitis accounts for 7 to 11% of chronic 
nasal diseases (Meler et al. 2008, Tasker et al. 1999, Lobetti 2009) 
and is most often caused by Aspergillus fumigatus (Peeters & 
Clercx 2007). Treatment of canine sinonasal aspergillosis (SNA) 
remains a challenge and no gold standard procedure has been 
established. Oral treatments with antifungal drugs (azole deriva-
tives) have generally poor to moderate efficacy, require prolonged 
administration and are commonly associated with adverse effects 
(Peeters & Clercx 2007). However, improved clinical remission 
rates were recently reported for combination treatment with 
posaconazole and terbinafine (Stewart & Bianco 2017). Treat-
ment with enilconazole or clotrimazole infusion administered 
topically through catheters placed surgically, blindly or endo-
scopically have been associated with higher success rates (Peeters 
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Minimally invasive protocols involve a thorough endoscopic 
debridement of the affected areas, followed by a 1-hour infusion 
of 1% clotrimazole or 1 to 2% enilconazole solutions through 
catheters placed either blindly into each nasal cavity (Mathews 
et al. 1998, Zonderland et al. 2002, Saunders et al. 2003, Schuller 
& Clercx 2007, Greci et al. 2008, Pomrantz & Johnson 2010, 
Sharman et al. 2010) or endoscopically into the affected frontal 
sinuses and/or nasal cavities (Mathews et al. 1996, McCullough 
et al. 1998, Saunders et al. 2003, Schuller & Clercx 2007). In 
some cases, further addition of 1% bifonazole cream instilled 
into the infusion catheter of the affected nasal cavity has been 
performed (Billen et al. 2010).
Treatment outcomes are difficult to compare due to the lack of 
a standardised definition of successful treatment (Billen & Peeters 
2017). In studies in which dogs were reassessed endoscopically, 
minimally invasive protocols showed positive outcomes in 46∙6 
to 85∙7% of cases after the first treatment and 89∙5 to 100% 
after multiple treatments (Zonderland et al. 2002, Saunders et al. 
2003, Schuller & Clercx 2007, Greci et al. 2008, Billen et al. 
2010).
Endoscopic therapeutic procedures are minimally invasive but 
are also laborious, time-consuming, require prolonged general 
anaesthesia and dogs are frequently hospitalised overnight fol-
lowing the procedure. Complications associated with the per-
endoscopic infusion of antifungal medication mainly include 
leakage of drug around infusion catheters with few negative con-
sequences (Zonderland et al. 2002) and, on rare occasions, bleed-
ing after withdrawal of the catheters (Zonderland et al. 2002, 
Mathews & Sharp 2006) or neurological signs due to leakage of 
antifungal solution into the cerebral cavity secondary to cribri-
form plate destruction (Peeters & Clercx 2007).
For protocols using surgically placed catheters, antifungal 
agents are instilled through a trephination site in the affected 
frontal sinuses (Mathews et al. 1998, Friend et al. 2002, Sissener 
et al. 2006, Pomrantz & Johnson 2010, Hazuchova et al. 2017). 
Such procedures may be necessary when the frontal sinus cannot 
be reached endoscopically. Frontal sinus trephination is a quicker 
but more invasive technique and does not improve treatment 
outcome compared to endoscopic procedures alone (Hazuchova 
et al. 2017).
Although previous minimally invasive protocols offer satisfac-
tory results, one of their most important drawbacks is the dura-
tion of the procedure, mainly related to the length of soak. As the 
soak time had been arbitrarily selected we first considered that a 
shorter soak period would be as efficacious. Moreover, incom-
plete debridement before application of topical treatment has 
been suggested as one of the reasons for treatment failure (Claeys 
et al. 2006, Billen et al. 2010, Sharman et al. 2010, Sharman 
et al. 2012, Sharman & Mansfield 2012). However, the impact 
of completeness of endoscopic debridement on outcome has not 
been previously reported.
Therefore, the first aim of this study was to investigate the 
effectiveness of a shorter infusion protocol (SP=simplified pro-
tocol) compared with the previously described 1-hour infusion 
protocol (PP=previous 1-hour protocol) (Billen et al. 2010). The 
second objective was to assess the usefulness of complete debride-
ment as part of the treatment (the benefit of complete endoscopic 
debridement) on first treatment success rate.
MATERIALS AND METHODS
Animals
Dogs presented to the institution between October 2006 and 
February 2015 with a definitive diagnosis of SNA and treated 
with a minimally invasive enilconazole infusion protocol were 
included in this study. In December 2011 it was decided to adopt 
a simplified form of the previously described infusion protocol. 
Consequently, from then on, all dogs with a first diagnosis of 
SNA were treated with the SP. Dogs treated before December 
2011 with the PP were used retrospectively as a control group. 
Dogs were included in the study if they had a confirmed diag-
nosis of SNA based on the presence of compatible clinical signs 
and per-endoscopic identification of fungal plaques with turbi-
nate destruction. Additional diagnostic procedures consisted of 
CT, histopathology, microscopic examination and fungal cul-
ture. Age, gender, breed, bodyweight and duration of clinical 
signs were recorded for each case. Presence or absence of systemic 
clinical signs was also noted when the information was available.
Anaesthesia
Dogs were pre-oxygenated and then premedicated with medeto-
midine (Sedator; Eurovet) intravenously (iv) alone, or a combina-
tion of medetomidine iv and butorphanol (Butomidor; Ecuphar) 
iv, or a combination of midazolam (Midazolam Mylan; Mylan) 
iv, methadone (Comfortan; Dechra) iv. and propofol (Diprivan; 
AstraZeneca) iv was used for induction, after which they were 
intubated and anaesthetic monitoring was implemented. Anaes-
thesia was maintained with isoflurane (Iso-Vet; Eurovet) (in 
oxygen). If necessary, atipamezole (Atipazole; Prodivet Pharma-
ceuticals) intramuscularly was used to reverse medetomidine at 
the end of the protocol.
Rhinoscopy
Under general anaesthesia, dogs were placed in sternal recum-
bency and rhinosinuscopy was performed using a paediatric 
bronchoscope (Paediatric bronchoscope Fujinon EB-4105; Onys 
SA) and/or a rigid endoscope (Cystoscope K Storz SL 30°, Ref 
BA 3059308; Karl-Storz-Endoscopy) appropriately to access to 
the nasal cavities and frontal sinuses depending on the size of the 
patient and the area to be scoped.
Debridement
In all dogs, debridement of the sinonasal cavities was performed 
using per-endoscopic forceps. Aspiration was performed using a 
suction device and a sterile saline solution was used for lavage. 
This procedure was performed by the same experienced operators 
throughout the study (FB and CC) and completeness of debride-
ment was systematically documented in the medical records as 
complete or partial. Debridement was considered complete if no 
macroscopic fungal plaques were visible at the end of the proce-
dure. Debridement was defined as partial when small amounts of 
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fungal material could not be removed due to limited endoscopic 
access to the sinus, limited visibility due to excessive bleeding or 
when removal of remaining fungal plaques was considered haz-
ardous for the endoscope, due to the presence of sharp splinters 
of turbinates.
Original (previous) protocol (before December 2011)
After debridement, the infusion procedure was performed as pre-
viously described by Billen et al. (2010). During this procedure 
the dog was placed in dorsal recumbency. A 24-Fr Foley catheter 
(Balloon Catheter; Teleflex Medical) was first inserted through 
the mouth into the nasopharynx with right-angle forceps and 
the 30 to 50 mL balloon was inflated, with gauze sponges placed 
behind the Foley catheter in the pharynx. A 12-Fr fenestrated 
infusion catheter (Suction Catheter; Servoprax GmbH) was then 
placed in both sinonasal cavities. If the frontal sinus was involved, 
the infusion catheter was placed endoscopically in the caudal part 
of the affected frontal sinus. If the fungal infection was restricted 
to one nasal cavity or both nasal cavities, the infusion catheter 
was placed blindly dorso-medially up to the level of the medial 
canthus of the eye. This was also the case in the unaffected con-
tralateral nasal cavity in case of unilateral involvement. Both nos-
trils were then occluded using separate 12-Fr Foley catheters. The 
infusion catheters were filled with the antifungal solution and 
connected using a T-shape connecting piece to a 60-mL infusion 
syringe. All Foley catheters were closed with clamps. Approxi-
mately 120 mL (60 mL in each nasal cavity) of a 2% enilconazole 
(Imaverol; Janssen-Cilag SA) solution was slowly infused manu-
ally in order to soak both sinonasal cavities for 60 minutes.
To maximise drug contact with all sinonasal surfaces, the dog 
was rotated every 15 minutes by 90°. At the end of the procedure 
the head was tilted downwards at an angle of 30° and infusion 
solution was allowed to drain through the nostrils for 10 min-
utes after the nasal Foley catheters were removed. Finally, a dose 
of 15 g 1% bifonazole cream (Canestene; Bayer) was adminis-
tered through the infusion catheter into the frontal sinus of the 
affected side(s) with the nose in upright position (head posi-
tioned at an angle of 90°) for at least 10 minutes. The infusion 
catheters, the nasopharyngeal Foley catheter and gauze sponges 
were then removed.
Simplified protocol (since December 2011)
After debridement, placement of the infusion catheters was simi-
lar to the PP but the dog was placed in dorsal recumbency with 
the head positioned at an angle of 90° (Fig. 1); Foley catheters 
were not needed for nostril occlusion. A dose of approximately 
120 mL (60 mL in each nasal cavity) of 2% enilconazole solution 
was slowly infused manually, until the solution was seen at the 
nostrils, in order to soak both sinonasal cavities for 15 minutes. 
Bifonazole cream was not administered.
At the end of the procedure, antibiotic therapy was started in 
all dogs with a dose of 20 mg/kg cefazoline (Cefazoline Sandoz; 
Sandoz) iv followed by oral treatment dose of 20 mg/kg cefal-
exine (Rilexine; Virbac) orally every 12 hours for 5  days. All 
dogs received oral antifungal treatment with a dose of 5 mg/kg 
itraconazole (Sporanox; Janssen-Cilag SA) orally every 12 hours 
FIG 1. Position of the dog during the simplified protocol. The dog is 
placed in dorsal recumbency with the head positioned at 90°. A Foley 
catheter was introduced into the nasopharynx (black arrowhead). Nasal 
infusion catheters (red arrowheads) were filled with 2% enilconazole 
solution until the solution appears at the edge of the nostrils (red arrow)
until re-evaluation of treatment success. The duration of anaes-
thesia was recorded in each case.
Outcome
Dogs were re-examined and rhinoscopy was repeated 3 to 
5 weeks after treatment. If there was a resolution of clinical signs 
and absence of fungal plaques at follow-up rhinoscopy, treatment 
was deemed successful and no more treatment was administered. 
If fungal plaques were detected, treatment was considered to have 
failed. In that case, debridement and a second identical infusion 
protocol were performed and a new follow-up rhinoscopy was 
scheduled 3 to 5 weeks later. In dogs in which endoscopic follow-
up was not performed 3 to 5 weeks after treatment, treatment 
success was based on the presence/absence of compatible clinical 
signs (established by telephone consultation).
Statistical analysis
Analyses were performed using logistic regression models where 
the outcome was first treatment failure. Crude odds ratios (OR) 
were calculated to quantify the associations between the outcome 
and both the type of protocol (PP/SP) and complete debride-
ment (yes/no). Separate bivariate logistic regression models were 
performed in order to remove potential confounding factors 
including the exposure of interest (protocol type or debridement) 
and one exposure among the following: age, sex, bodyweight, 
duration of clinical signs and presence of systemic signs. Time 
of anaesthesia between the two groups were compared using a 
Mann-Whitney U test. For all analysis, a threshold of P<0∙05 
was considered statistically significant. Data were analysed using 
SAS® V9∙3 (SAS Institute) software.
E. Vangrinsven et al.
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Table 2. Short- and long-term outcome of 48 dogs with sinonasal aspergillosis
Treatment success after  
one infusion procedure*
Treatment success after  
two infusion procedures
Euthanased Overall treatment  
success
PP (n = 24) 58∙3% (n=14) 37∙5% (n=9) 4∙2% (n=1) 96% (n=23)
SP (n=24) 62∙5% (n=15) 33∙3% (n=8) 4∙2% (n=1) 96% (n=23)
Complete debridement (n=28) 75% (n=21) 25% (n=7) 0% 100% (n=28)
Partial debridement (n=20) 40% (n=8) 50% (n=10) 10% (n=2) 90% (n=18)
PP previous protocol, SP simplified protocol
*Short-term assessment by rhinoscopy or long-term assessment through telephone consultation in six dogs (40 to 127 months after infusion protocol)
RESULTS
Animals
Forty-eight dogs were included. During the study period, 35 
additional dogs with a presumptive or definitive diagnosis of 
canine SNA were presented to the institution. These cases did 
not meet the inclusion criteria (unconfirmed diagnosis, surgical 
rhinotomy or infusion refused by the owners for financial con-
cerns) and were not included.
The median age of the dogs at initial presentation was 5∙5 years 
(range 9 months to 12 years), with 33 males (11 neutered) and 15 
(six neutered) females. The most frequently represented breeds 
included the rottweiler (n=9), golden retriever (n=6), beauceron 
(n=3), Labrador retriever (n=3) and Border collie (n=3). The 
median bodyweight was 29∙2 kg (range 13 to 55 kg). Reported 
duration of clinical signs before treatment ranged from 1 to 
40 weeks (median 9∙5 weeks). Distributions of age, gender, body-
weight and duration of clinical signs were similar between the 
two groups (Table 1). At the time of diagnosis, 50% (23/46) of 
dogs presented systemic clinical signs including lethargy, reduced 
appetite, weight loss and/or mild hyperthermia. This informa-
tion was lacking in two dogs (one in each group). Local clini-
cal features included sneezing (n=25) or reverse sneezing (n=4), 
uni- or bilateral nasal discharge (n=42), uni- or bilateral epistaxis 
(n=9), hyperkeratosis (n=9), signs of nasal pain (n=14), nasal pla-
num depigmentation (n=12) and nasal planum erosion (n=7).
Rhinoscopy and CT
CT was performed in 31% (n=15) of cases, with no evidence of 
perforation of the cribriform plate in any case. Nasal turbinate 
destruction and fungal plaques were endoscopically observed in 
all dogs. Unilateral SNA was diagnosed in 35 cases (73%), bilat-
eral SNA in five (10%), unilateral nasal aspergillosis (i.e. fungal 
Table 1. Signalment, presence of systemic signs and 
duration of clinical signs in dogs treated with the PP and 
the SP
PP (n=24) SP (n=24)
Age (years) 5∙5 (1∙5 to 12) 5∙5 (0∙8 to 11)
Bodyweight (kg) 29∙5 (14∙5 to 55) 29∙2 (16∙8 to 52)
Gender Nine females and 
15 males
Six females and 
18 males
Presence of systemic signs 10 13
Duration of clinical signs 
before treatment (weeks)
11 (3 to 40)* 9 (1 to 24)*
PP previous protocol, SP simplified protocol
*Median (ranges) or absolute values
infection restricted to the nasal cavity) in three (6%) and bilateral 
nasal aspergillosis in four (8%) of dogs. In one case, the infection 
was sinonasal on one side with an extension to the nasal cavity 
on the contralateral side through destruction of the nasal septum.
Treatment and outcome
Twenty-four dogs were treated with the SP and 24 dogs with the 
PP. The sinus was accessible and the infusion catheter(s) could 
be placed endoscopically in all but two dogs (n=39; 81%) with 
SNA, both belonging to the SP group. Of the 48 dogs, 42 dogs 
were re-examined – including a recheck rhinoscopy 3 to 5 weeks 
after treatment. Two dogs, one in each group, were euthana-
sed after failure of the first treatment and the owner’s decision 
not to pursue further treatment (Table  2). For six dogs (three 
per group), recheck rhinoscopy was declined by the owner for 
financial or personal reasons although in all six cases there was 
a reported resolution of clinical signs. For the six dogs in which 
recheck rhinoscopy could not be performed at 3 to 5 weeks, long-
term follow-up through telephone consultation, between 40 and 
127 months after their infusion protocol, demonstrated that they 
did not show recurrence of clinical signs of nasal disease. In these 
dogs, the infusion protocol was considered successful after one 
treatment. Systemic antifungal treatment was stopped in all cases 
either at time of recheck endoscopy, considered to be successful 
treatment, or 3 to 5 weeks after the infusion protocol in the six 
dogs in which recheck endoscopy could not be performed.
Median duration of anaesthesia was 200 minutes (range 120 
to 265) for the PP and 85 minutes (range 40 to 140) for the SP 
(P<0∙0001). With the SP, recovery from anaesthesia was shorter 
and all dogs were ready for discharge on the same day. The SP 
was well tolerated in all dogs and did not cause any significant 
adverse effects.
Overall first treatment success rate was 60% (n=29), and over-
all treatment success rate was 96% (n=46). No dog received more 
than two infusion protocols. The first treatment success rate in 
the PP group was 58% (n=14) compared to 62∙5% (n=15) for 
the SP group (Table 2). The overall treatment success rate (after 
one/two infusion protocols) was 96% (n=23) in both groups. 
The first treatment failure rate was not significantly different 
between treatment groups (SP: 37∙5% versus PP: 42%, OR 0∙84, 
CI 0∙26 to 2∙68, P=0∙77). In separated bivariate models, after 
adjustment for each of the potential confounders (age, body-
weight, gender, presence of systemic signs or duration of clinical 
signs), the treatment remained not significantly associated with 
the outcome, with adjusted OR comparing SP dogs versus PP 
dogs always lower than 1.
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The effect of completeness of endoscopic debridement on first 
treatment success rate was evaluated for all 48 dogs. Endoscopic 
debridement was complete in 60% (n=28) of dogs. First treat-
ment failure rate was lower in dogs with complete debridement 
(25%) compared to dogs with partial debridement (60%) (OR 
0∙24, CI 0∙07 to 0∙85, P=0∙03). In separated bivariate models, 
adjustment for each of the dog exposures (age, bodyweight, gen-
der, presence of systemic signs or duration of clinical signs) still 
resulted in a significant effect of completeness of debridement.
DISCUSSION
Despite a reduced contact time and removal of the use of bifon-
azole cream for the SP, the results revealed a similar treatment 
success rate – 96% – and similar first treatment success rates – 
~60% – for the two techniques. These results are similar to previ-
ously reported first treatment success rates of 46∙6 to 76∙6% for 
SNA (Schuller & Clercx 2007, Greci et al. 2008).
The primary objective of this study was to determine whether 
a shorter procedure could be performed without compromis-
ing treatment efficacy. At this institution a minimally invasive 
approach has been preferred over surgical trephination for some 
years due to reduced trauma to patient and because it has been 
associated with fewer complications (subcutaneous emphy-
sema, infection) (Mathews et al. 1998, McCullough et al. 1998, 
Zonderland et al. 2002, Peeters & Clercx 2007, Sharman & 
Mansfield 2012). A recent study (Hazuchova et al. 2017) showed 
that trephination did not influence the number of treatments 
necessary for resolution of the disease among dogs with success-
ful outcomes.
The major disadvantages associated with a minimally invasive 
approach have been prolonged anaesthesia leading, potentially, to 
increased anaesthetic risk, prolonged recovery and patient cool-
ing. Duration of anaesthesia was substantially shorter (mean dif-
ference of 109 minutes) in the SP compared to that in the PP. 
This time reduction was mainly achieved by simplifying the set-
up of the procedure and by reducing the drug contact time from 
1 hour to 15 minutes. Preparation of the patient for the antifungal 
infusion was easier and faster in the SP compared to that in the 
PP. Foley catheters for nostril occlusion were not needed in the 
SP and nasal Foley catheter adjustment was frequently required 
during the PP infusion due to leakage of the antifungal solution 
through the nostrils. Additionally, in the SP the dog remained 
in dorsal recumbency throughout the infusion and bifonazole 
cream was not administered. It has been reported previously that 
the addition of bifonazole cream did not seem to improve first 
treatment success rate (Billen et al. 2010).
For the SP, the dog was maintained in dorsal recumbency 
with the head angled upwards at 90°. Mathews et al. (1996) per-
formed a study in which dogs were similarly positioned in dorsal 
recumbency and the head rotated successively to the right and 
left side for 15 minutes per side. Postinfusion CT images con-
firmed infusion solution throughout all areas of both frontal 
sinuses and nasal cavities. Although there are differences with the 
positioning used in this study (absence of rotation of the head) 
we expect to have reached a similar drug distribution with this 
approach. Ideal contact times for successful therapy have not yet 
been established (Sharman & Mansfield 2012), and we decided 
to maintain the 15 minutes contact period with each mucosal 
surface described in the previous protocol. Since enilconazole was 
infused until it appeared at the nostrils, we were confident that 
the solution completely filled all areas of the sinonasal cavities 
ensuring contact of the drug with all mucosal surfaces during the 
15 minutes of infusion.
The second objective of our study was to address the impor-
tance of completeness of the debridement. In people, non-inva-
sive forms of fungal rhinosinusitis can be managed with surgical 
debridement as a sole treatment (Uri et al. 2003). In dogs, exten-
sive rhinoscopic debridement before infusion is considered 
an important element determining therapeutic success. How-
ever, to our knowledge, it has not previously been investigated 
(Zonderland et al. 2002, Sharman et al. 2010, Sharman et al. 
2012). In the present study, we showed a significant improve-
ment in first treatment success rate when complete debridement 
was achieved. The results of this study strongly support complete 
debridement being a critical point for therapeutic success. How-
ever, since this was an observational study, residual confounding 
bias or reverse causality cannot be ruled out and causal inference 
must be made with caution – for instance, less severe cases may 
be easier to debride.
In this study, when debridement was reported as being com-
plete, the clinician was confident that no residual fungal or 
necrotic material had been missed as the entirety of the nasal cav-
ity (uni- or bilaterally) and sinus(es) could be explored. However, 
in a study by Sharman et al. (2010), CT demonstrated significant 
residual disease even if debridement was considered complete on 
visual assessment by rhinoscopy, which makes the degree of accu-
racy of the latter questionable. Completeness of debridement was 
not determined by CT in this study, consequently, in dogs with 
complete debridement first treatment failure could potentially 
have been due to residual disease not detected during rhinoscopic 
evaluation. CT could have been an interesting tool to assign dif-
ferent levels for partial debridement and evaluate the potential 
association between outcome and debridement level.
Association between younger age and treatment success was 
the only significant factor described to influence outcome in a 
prospective multi-centre study (Sharman et al. 2010). In our 
study the important factors we identified remained significant 
after adjustment for potential confounding factors including age.
Finally, a substantial variability and asymmetry in frontal sinus 
and nasal cavity anatomy between and within individual dogs has 
been demonstrated (Burrow et al. 2011) which may influence 
distribution and retention of antifungal agents and, therefore, 
outcome (Sharman & Mansfield 2012). This could be another 
explanation for treatment failure in dogs in which debridement 
was considered to be complete in our study. The infusion cath-
eter localisation (blindly in the nasal cavity or endoscopically in 
the affected frontal sinus) is unlikely to have affected the results 
because the frontal sinus was accessible and the catheter was placed 
endoscopically within the sinus in almost all dogs (except two in 
the SP group) with unilateral or bilateral SNA. A prospective 
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cohort study involving more dogs and designed to examine all 
potential confounding factors is warranted to confirm our pre-
liminary results.
Antibiotic therapy was prescribed in all dogs following treat-
ment. This may be considered controversial, because some 
reports describing treatment of SNA advise against the use of 
antibiotics as part of good antimicrobial stewardship. However, 
the extensive local necrosis, lysis and bleeding might represent 
an increased risk for secondary bacterial infection. A study by 
De Lorenzi et al. (2006) found neutrophilic inflammation, free 
bacteria and phagocytosed bacteria in 100% of nasal cytology 
preparations from dogs with SNA, suggesting secondary bacterial 
infection. Furthermore, as antimicrobial treatment was part of 
the previously described protocol (Billen et al. 2010), we decided 
to maintain the same treatment after infusion for the SP group 
to facilitate comparison of these two protocols. The prescription 
of oral antifungal medication after infusion protocol in all dogs 
was based on the assumption that it could contribute to better 
control of the disease (Claeys et al. 2006).
It has been shown that Aspergillus plaques still can be found in 
nasal cavities/sinuses at follow-up rhinoscopy, despite the absence 
of overt clinical signs (Zonderland et al. 2002). A limitation of 
the present study was the absence of follow-up rhinoscopy in a 
small number of dogs. In six cases the owners declined a recheck 
endoscopy. However, the absence of clinical signs of nasal disease 
for 40 to 127 months was strongly suggestive of treatment success 
in these animals.
In conclusion, the SP seems a promising alternative approach 
for the treatment of canine SNA. Complete debridement of the 
fungal plaques before infusion of antifungal medication appears 
critical for therapeutic success in canine SNA.
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